SPECT/CT in Endocrine and Neuroendocrine Tumors

This study has been completed.
Sponsor:
Information provided by:
Rambam Health Care Campus
ClinicalTrials.gov Identifier:
NCT00230139
First received: September 29, 2005
Last updated: October 11, 2008
Last verified: September 2005

September 29, 2005
October 11, 2008
January 2002
January 2004   (final data collection date for primary outcome measure)
The impact of imaging modality on patient management [ Designated as safety issue: Yes ]
The impact of imaging modality on patient management
Complete list of historical versions of study NCT00230139 on ClinicalTrials.gov Archive Site
The impact of imaging modality on patient management [ Designated as safety issue: Yes ]
Not Provided
Not Provided
Not Provided
 
SPECT/CT in Endocrine and Neuroendocrine Tumors
The Added Value of SPECT/CT in the Evaluation of Endocrine and Neuroendocrine Tumors

The value of fusion of functional and anatomical data has been described using several fusion techniques for various nuclear medicine procedures and morphologic imaging modalities (SPECT-CT, SPECT-MRI, Coincidence-CT). We hypothesize that NM -CT data has advantages over the data obtained using separately performed NM study and conventional anatomic imaging as CT. We hypothesize that more accurate localization of the radio-isotope activity on NM images will improve diagnostic accuracy and will have an impact on patient management:

Improved accuracy of NM study will improve tumor localization, the evaluation of the extent of disease and the post therapy follow up.

It will direct other diagnostic procedures to lesions otherwise undetected, or exclude the need for more invasive procedures. It can also guide invasive procedures and radiation-therapy planning, thus improving therapy results and avoiding unnecessary treatment-related side effects.

The value of fusion of functional and anatomical data has been described using several fusion techniques for various nuclear medicine procedures and morphologic imaging modalities (SPECT-CT, SPECT-MRI, Coincidence-CT). We hypothesize that NM -CT data has advantages over the data obtained using separately performed NM study and conventional anatomic imaging as CT. We hypothesize that more accurate localization of the radio-isotope activity on NM images will improve diagnostic accuracy and will have an impact on patient management:

Improved accuracy of NM study will improve tumor localization, the evaluation of the extent of disease and the post therapy follow up.

It will direct other diagnostic procedures to lesions otherwise undetected, or exclude the need for more invasive procedures. It can also guide invasive procedures and radiation-therapy planning, thus improving therapy results and avoiding unnecessary treatment-related side effects.

Interventional
Not Provided
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Diagnostic
Endocrine and Neuroendocrine Tumors
Device: SPECT/CT
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
200
January 2006
January 2004   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Patient referred for NM scintigraphy to assess the presence of endocrine or neuroendocrine tumors.
  • Patient signed informed consent

Exclusion Criteria:

  • The study will not be performed in pregnant or lactating women.
  • Patient will not be able or willing to tolerate the scan until its completion.
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
Israel
 
NCT00230139
endocrineCTIL
Not Provided
Rambam Health Care Campus
Rambam Health Care Campus
Not Provided
Principal Investigator: Zohar Keidar, MD,PhD Rambam Health Care Campus
Rambam Health Care Campus
September 2005

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP